Unicycive Therapeutics Inc. (NASDAQ: UNCY)
$0.49
-0.0118 ( -2.36% ) 279.7K
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.
Market Data
Open
$0.49
Previous close
$0.50
Volume
279.7K
Market cap
$41.23M
Day range
$0.48 - $0.49
52 week range
$0.34 - $1.82
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 12 | Aug 31, 2023 |
4 | Insider transactions | 1 | Aug 30, 2023 |
4 | Insider transactions | 1 | Aug 30, 2023 |
4 | Insider transactions | 1 | Aug 30, 2023 |
4 | Insider transactions | 1 | Aug 30, 2023 |
8-k | 8K-related | 13 | Aug 15, 2023 |
10-q | Quarterly Reports | 74 | Aug 14, 2023 |
8-k | 8K-related | 13 | Jul 31, 2023 |
8-k | 8K-related | 12 | Jul 26, 2023 |
4 | Insider transactions | 1 | Jul 13, 2023 |